Dapagliflozin Combined with Liraglutide vs Monotherapy in Obese Patients with Heart Failure
Zhou G, Liu A, Hu X, et al.
Summary
Combination therapy of dapagliflozin (SGLT2 inhibitor) with liraglutide showed superior outcomes compared to monotherapy in obese patients with heart failure.
Clinical Significance
Supports the growing evidence for GLP-1/SGLT2 inhibitor combination therapy in cardiometabolic patients.
Study Overview
This study compared the efficacy of dapagliflozin combined with liraglutide versus either drug alone in obese patients with heart failure.
Key Findings
Combination Therapy Benefits
- Greater weight loss than either agent alone
- Improved cardiac function markers
- Better glycemic control
- Reduced hospitalization rates
Safety Profile
- Combination was well tolerated
- No unexpected adverse events with combination use
Clinical Relevance
Combining GLP-1 receptor agonists with SGLT2 inhibitors is increasingly recognized as an effective strategy for patients with overlapping obesity, diabetes, and heart failure.
Source
Kapcsolódó kutatás
GLP-1 Analogs Activate AMP Kinase Leading to Reversal of the Warburg Effect in Breast Cancer Cells
GLP-1 receptor agonists were shown to activate AMP kinase and reverse the Warburg metabolic switch i…
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis evaluated the association between GLP-1 receptor agonist use and de…
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…
Exposure-Adjusted Safety and Efficacy of GLP-1 and GLP-1/GIP Receptor Agonists for Weight Management and Type 2 Diabetes
This comprehensive analysis of FDA regulatory data across 14 medications and over 34,000 safety subj…